Benzinga | Mar 4, 2021 08:07AM EST

JMP Securities Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $160

JMP Securities analyst Silvan Tuerkcan initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform rating and announces Price Target of $160.